[Real-life experiences with Brolucizumab in recalcitrant neovascular age-related macular degeneration]. / Erste Erfahrungen mit Brolucizumab bei neovaskulärer altersabhängiger Makuladegeneration und Therapierefraktärität unter der bisherigen Anti-VEGF-Therapie.
Ophthalmologe
; 119(3): 258-264, 2022 Mar.
Article
in De
| MEDLINE
| ID: mdl-34351479
ABSTRACT
BACKGROUND:
Pivotal clinical trials have proven brolucizumab to be a potent intravitreal anti-vascular endothelial growth factor (VEGF) drug in patients with neovascular age-related macular degeneration (nAMD). Therefore, it seems to be a promising drug also in patients with recalcitrant nAMD. This article presents the results of patients who were switched to brolucizumab due to persistent fluid under previous anti-VEGF treatment.METHODS:
In this study 21 eyes were retrospectively analyzed in which treatment was switched to brolucizumab due to persistent intraretinal (IRF), subretinal (SRF) and/or sub-retinal pigment epithelium (sub-RPE fluid) fluid despite long-term anti-VEGF treatment. Functional and spectral domain optical coherence tomography (SD-OCT) data were investigated at diagnosis of nAMD (I), at switch to brolucizumab (II), 4 weeks after upload of brolucizumab (III) and at first reactivation of macular neovascularization (MNV, IV).RESULTS:
There were no significant changes in fluid distribution between (I) and (II). After upload of brolucizumab (III) a significant reduction of central subfield retinal thickness (CSRT, pâ¯= 0.0001), SRF (pâ¯= 0.004) and sub-RPE fluid (pâ¯= 0.04), but no visual acuity improvement (pâ¯= 0.56) were observed.CONCLUSION:
Intravitreal brolucizumab treatment can achieve significant reductions particularly of SRF and sub-RPE in patients refractory to previous anti-VEGF treatment. Future studies should further investigate the effects of brolucizumab in patients with recalcitrant nAMD.Key words
Full text:
1
Database:
MEDLINE
Main subject:
Wet Macular Degeneration
/
Macular Degeneration
Type of study:
Diagnostic_studies
/
Observational_studies
Limits:
Humans
Language:
De
Year:
2022
Type:
Article